A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
- Conditions
- Overactive Bladder
- Interventions
- Registration Number
- NCT03492281
- Lead Sponsor
- Urovant Sciences GmbH
- Brief Summary
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1530
- Has a history of OAB for at least 3 months prior to the Screening Visit.
- Meets either the OAB Wet or OAB Dry criteria.
Urology Medical History
- Patient had an average total daily urine volume > 3000 mL in the past 6 months or during the 14-day Run-in Period.
- Has lower urinary tract pathology that could, in the opinion of the Investigator, be responsible for urgency, frequency, or incontinence.
- Has a history of surgery to correct stress urinary incontinence, pelvic organ prolapse, or procedural treatments for BPH within 6 months of Screening.
- Has current history or evidence of Stage 2 or greater pelvic organ prolapse (prolapse extends beyond the hymenal ring).
- Patient is currently using a pessary for the treatment of pelvic organ prolapse.
- Has a known history of elevated post-void residual volume defined as greater than 150 mL.
- Has undergone bladder training or electrostimulation within 28 days prior to Screening or plans to initiate either during the study.
- Has an active or recurrent (> 3 episodes per year) urinary tract infection by clinical symptoms or pre-defined laboratory criteria.
- Has a requirement for an indwelling catheter or intermittent catheterization.
- Has received an intradetrusor injection of botulinum toxin within 9 months prior to Screening.
- Has uncontrolled hyperglycemia (defined as fasting blood glucose > 150 mg/dL or 8.33 mmol/L and/or non-fasting blood glucose > 200 mg/dL or 11.1 mmol/L) or, if in the opinion of the Investigator, is uncontrolled.
- Has evidence of diabetes insipidus.
- Is pregnant, breast-feeding, or is planning to conceive within the projected duration of the study.
- Has a concurrent malignancy or history of any malignancy within 5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
- Has uncontrolled hypertension (systolic blood pressure of ≥ 180 mmHg and/or diastolic blood pressure of ≥ 100 mmHg) or has a resting heart rate (by pulse) > 100 beats per minute.
- Has narrow angle glaucoma (primary open angle glaucoma is not excluded).
- Has a history of cerebral vascular accident, transient ischemic attack, unstable angina, myocardial infarction, coronary artery interventions (e.g., coronary artery bypass grafting or percutaneous coronary interventions [e.g., angioplasty, stent insertion]), or neurovascular interventions (e.g., carotid artery stenting) within 6 months prior to the Screening Visit. Has a known history of liver disease.
- Has a history of injury, surgery, or neurodegenerative diseases (e.g., multiple sclerosis, Parkinson's) that could affect the lower urinary tract or its nerve supply.
- Has hematuria, including microscopic hematuria according to pre-defined criteria.
- Has clinically significant electrocardiogram (ECG) abnormality.
- Has alanine aminotransferase or aspartate aminotransferase > 2.0 times the upper limit of normal (ULN), or bilirubin (total bilirubin) > 1.5 x ULN (or > 2.0 x ULN if secondary to Gilbert syndrome or pattern consistent with Gilbert syndrome).
- Has an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2.
- Has an allergy, intolerance, or a history of a significant clinical or laboratory adverse experience associated with any of the active or inactive components of the vibegron formulation or tolterodine formulation.
- Is currently participating or has participated in a study with an investigational compound or device within 28 days prior to signing informed consent, or has participated in any previous study with vibegron.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Vibegron + Placebo to match Tolterodine Tolterodine placebo - Placebo to match vibegron + Placebo to match Tolterodine Vibegron placebo - Placebo to match vibegron + Placebo to match Tolterodine Tolterodine placebo - Tolterodine + Placebo to match vibegron Vibegron placebo - Tolterodine + Placebo to match vibegron Tolterodine Tartrate ER - Vibegron + Placebo to match Tolterodine vibegron -
- Primary Outcome Measures
Name Time Method Change From Baseline (CFB) at Week 12 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) Participants Baseline (BL); Week 12 A micturition/void is defined as "Urinated in Toilet" as indicated on the Patient Voiding Diary (PVD). The number of micturitions is defined as the number of times a participant voided in the toilet as indicated on the PVD. The average daily number of micturitions was calculated using the daily entries in the PVD (which was to be completed prior to each study visit) as the total number of micturitions that occurred on a Complete Diary Day (CDD) divided by the number of CDDs in the PVD. CFB was calculated as the post-BL value minus the BL value. "Per 24 hours" corresponds to one Diary Day (i.e., time between when the participant got up for the day each morning and time the participant got up for the day the next morning as recorded in the PVD). Covariates included in the mixed model for repeated measures are study visit (Weeks 2, 4, 8, and 12), OAB type (wet/dry), sex, region (U.S./non-U.S.), BL number of micturitions, and treatment by study visit interaction. FAS=Full Analysis Set.
CFB at Week 12 in the Average Number of Urge Urinary Incontinence (UUI) Episodes Per 24 Hours in OAB Wet Participants Baseline; Week 12 The number of UUI episodes is defined as the number of times a participant had checked "urge" as the main reason for the leakage in the PVD, regardless of whether more than one reason for leakage in addition to "urge" was checked. The average daily number of UUI episodes was calculated using the daily entries in the PVD (which was to be completed prior to each study visit) as the total number of UUI episodes that occurred on a CDD divided by the number of CCDs in the PVD. CFB was calculated as the post-BL value minus the BL value. "Per 24 hours" corresponds to one Diary Day (i.e., time between when participant got up for the day each morning and time participant got up for the day the next morning as recorded in the PVD). Covariates included in the mixed model for repeated measures were study visit (Weeks 2, 4, 8, and 12), sex, region (U.S./non-U.S.), BL number of UUI episodes and treatment by study visit interaction. FAS-I=Full Analysis Set for Incontinence.
- Secondary Outcome Measures
Name Time Method CFB at Week 12 in the Average Number of Urgency Episodes Over 24 Hours in All OAB Participants Baseline; Week 12 An urgency episode is defined as the "Need to Urinate Immediately" as indicated on the PVD. CFB is calculated as the post-BL value minus the BL value. "Over 24 hours" corresponds to one Diary Day (i.e., time between when the participant got up for the day each morning and time the participant got up for the day the next morning as recorded in the PVD). Covariates included in the mixed model for repeated measures were study visit (Weeks 2, 4, 8, and 12), OAB type (wet/dry), sex, region (U.S./non-U.S.), BL number of urgency episodes, and treatment by study visit interaction.
Percentage of OAB Wet Participants With at Least a 75% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12 Baseline; Week 12 The number of UUI episodes is defined as the number of times a participant had checked "urge" as the main reason for the leakage in the PVD, regardless of whether more than one reason for leakage in addition to "urge" was checked. The average daily number of UUI episodes was calculated using the daily entries in the PVD (which was to be completed prior to each study visit) as the total number of UUI episodes that occurred on a CDD divided by the number of CCDs in the PVD. CFB was calculated as the post-BL value minus the BL value. "Per 24 hours" corresponds to one Diary Day (i.e., time between when participant got up for the day each morning and time participant got up for the day the next morning as recorded in the PVD).
Percentage of OAB Wet Participants With a 100% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12 Baseline; Week 12 The number of UUI episodes is defined as the number of times a participant had checked "urge" as the main reason for the leakage in the PVD, regardless of whether more than one reason for leakage in addition to "urge" was checked. The average daily number of UUI episodes was calculated using the daily entries in the PVD (which was to be completed prior to each study visit) as the total number of UUI episodes that occurred on a CDD divided by the number of CCDs in the PVD. CFB was calculated as the post-BL value minus the BL value. "Per 24 hours" corresponds to one Diary Day (i.e., time between when participant got up for the day each morning and time participant got up for the day the next morning as recorded in the PVD).
Percentage of All OAB Participants With at Least a 50% Reduction From Baseline in Urgency Episodes Per 24 Hours at Week 12 Baseline; Week 12 An urgency episode is defined as the "Need to Urinate Immediately" as indicated on the PVD. CFB is calculated as the post-BL value minus the BL value. "Per 24 hours" corresponds to one Diary Day (i.e., time between when the participant got up for the day each morning and time the participant got up for the day the next morning as recorded in the PVD).
CFB at Week 12 in the Average Number of Total Incontinence Episodes Over 24 Hours in OAB Wet Participants Baseline; Week 12 Total incontinence is defined as having any reason for "Accidental Urine Leakage" and/or "Accidental Urine Leakage" checked, as indicated on the PVD. It is assumed that if the participant recorded a reason for leakage then the accidental urine leakage occurred. CFB is calculated as the post-BL value minus the BL value. "Over 24 hours" corresponds to one Diary Day (i.e., time between when the par. got up for the day each morning and time the par. got up for the day the next morning as recorded in the PVD). Covariates included in the mixed model for repeated measures were study visit (Weeks 2, 4, 8, and 12), sex, region (U.S./non-U.S.), BL number of incontinence episodes, and treatment by study visit interaction. hr = hours.
CFB at Week 12 in the Coping Score From the Overactive Bladder Questionnaire Long Form (OAB-q LF, 1-week Recall) in All OAB Participants Baseline; Week 12 The OAB-q LF is a validated patient-reported outcome. 8 questions of the OAB-q LF ask participants how well they have coped with their bladder symptoms during the previous week, as a measure of quality of life. Each question has a response ranging from "not coping" (= 1) to "coping well" (= 6). These questions make up the coping scale. The raw score (sum of question scores \[ranging from 8 to 48\]) is transformed to a unified score, ranging from 0 to 100. Higher scores correspond to a higher quality of life, and lower scores represent a lower quality of life. CFB is calculated as the post-BL value minus the BL value. Covariates included in the mixed model for repeated measures were study visit (Weeks 2, 4, 8, and 12), sex, region (U.S./non-U.S.), OAB type (wet/dry), BL score, and treatment by study visit interaction.
CFB at Week 12 in the Average Volume Voided Per Micturition in All OAB Participants Baseline; Week 12 A micturition/void is defined as "Urinated in Toilet" as indicated on the PVD. The number of micturitions is defined as the number of times a participant voided in the toilet as indicated on the PVD. CFB is calculated as the post-BL value minus the BL value. Covariates included in the mixed model for repeated measures were study visit (Weeks 2, 4, 8, and 12), OAB type (wet/dry), sex, region (U.S./non-U.S.), BL volume (milliliters \[mL\]), and treatment by study visit interaction.
CFB at Week 12 in the Health-related Quality of Life (HRQL) Total Score From the OAB-q LF (1-week Recall) in All OAB Participants Baseline; Week 12 The OAB-q LF is a validated patient-reported outcome. The 25 questions comprising the Coping, Concern, Sleep and Social Interaction subscales of the OAB-q LF ask participants how much their symptoms have affected their life over the last week. Each question has a response ranging from "None of the time" (= 1) to "All of the time" (= 6). The raw score (sum of question scores for the 4 subscales \[ranging from 25 to 150\]) is transformed to a unified score, ranging from 0 to 100. Higher scores correspond to a higher quality of life, and lower scores represent a lower quality of life. CFB is calculated as the post-BL value minus the BL value. Covariates included in the mixed model for repeated measures were study visit (Weeks 2, 4, 8, and 12), sex, region (U.S./non-U.S.), OAB type (wet/dry), BL score, and treatment by study visit interaction.
CFB at Week 12 in the Symptom Bother Score From the OAB-q LF (1-week Recall) in All OAB Participants Baseline; Week 12 The OAB-q LF is a validated patient-reported outcome. The first 8 questions of the OAB-q LF ask participants how much they were bothered by their bladder symptoms during the previous week. Each question has a response ranging from "Not at all" (= 1) to "A very great deal" (= 6). These questions make up the symptom bother scale. The raw score (sum of question scores \[ranging from 8 to 48\]) is transformed to a unified score, ranging from 0 to 100. Higher scores correspond to the symptoms having a larger bother, and lower scores represent a lower amount of bother due to symptoms. CFB is calculated as the post-BL value minus the BL value. Covariates included in the mixed model for repeated measures were study visit (Weeks 2, 4, 8, and 12), sex, region (U.S./non-U.S.), OAB type (wet/dry), BL score, and treatment by study visit interaction.
Percentage of All OAB Participants With an Average Number of Micturitions < 8 Per 24 Hours at Week 12 Week 12 A micturition/void is defined as "Urinated in Toilet" as indicated on the PVD. The number of micturitions is defined as the number of times a participant voided in the toilet as indicated on the PVD. A participant was defined as having an average of \< 8 daily micturitions if the arithmetic mean of the number of micturitions per day in the PVD was less than 8 . "Per 24 hours" corresponds to one Diary Day (i.e., time between when the participant got up for the day each morning and time the participant got up for the day the next morning as recorded in the PVD).
Percentage of OAB Wet Participants With at Least a 50% Reduction From Baseline in Total Incontinence Episodes Per 24 Hours at Week 12 Baseline; Week 12 Total incontinence is defined as having any reason for "Accidental Urine Leakage" and/or "Accidental Urine Leakage" checked, as indicated on the PVD. It is assumed that if the participant recorded a reason for leakage then the accidental urine leakage occurred. All events marked as having leakage, regardless of cause, or where "Accidental Leakage" was checked. were used in the analysis. "Per 24 hours" corresponds to one Diary Day (i.e., time between when the participant got up for the day each morning and time the participant got up for the day the next morning as recorded in the PVD.
CFB at Week 12 in Overall Bladder Symptoms Based on Patient Global Impression of Severity (PGI-Severity) in All OAB Participants Baseline; Week 12 The Patient Global Impression (PGI) questions are designed to assess a participant's overall impression of OAB. For the PGI-Severity score, participants are asked to rate their OAB symptoms over the previous week with one of the following responses: 1 = none, 2 = mild, 3 = moderate, 4 = severe. CFB is calculated as the post-BL value minus the BL value. Covariates included in the mixed model for repeated measures were study visit (Weeks 2, 4, 8, and 12), OAB type (wet/dry), sex, region (U.S./non-U.S.), BL score, and treatment by study visit interaction.
CFB at Week 12 in Overall Control Over Bladder Symptoms Based on Patient Global Impression of Control (PGI-Control) in All OAB Participants Baseline; Week 12 The Patient Global Impression (PGI) questions are designed to assess a participant's overall impression of OAB. For the PGI-Control score, participants were asked to rate how much control they had over their OAB symptoms over the previous week with one of the following responses: 1 = complete control, 2 = a lot of control, 3 = some control, 4 = only a little control, 5 = no control. CFB is calculated as the post-BL value minus the BL value. Covariates included in the mixed model for repeated measures were study visit (Weeks 2, 4, 8, and 12), OAB type (wet/dry), sex, region (U.S./non-U.S.), BL score, and treatment by study visit interaction.
Trial Locations
- Locations (204)
Prime-Care Clinical Research
🇺🇸Laguna Hills, California, United States
KO Clinical Research
🇺🇸Fort Lauderdale, Florida, United States
Vital Pharm Research Inc.
🇺🇸Hialeah, Florida, United States
Best Quality Research, Inc.
🇺🇸Hialeah, Florida, United States
South Broward Research LLC
🇺🇸Pembroke Pines, Florida, United States
Buckeye Health and Research
🇺🇸Columbus, Ohio, United States
Aventiv Research, Inc.
🇺🇸Columbus, Ohio, United States
Research Protocol Management Specialists Hills ObGyn Associates Inc
🇺🇸Pittsburgh, Pennsylvania, United States
Advances in Health
🇺🇸Houston, Texas, United States
BI Research Center
🇺🇸Houston, Texas, United States
Pioneer Research Solutions
🇺🇸Houston, Texas, United States
Boston Clinical Trials
🇺🇸Boston, Massachusetts, United States
Seattle Women's: Health, Research, Gynecology
🇺🇸Seattle, Washington, United States
San Marcus Research Clinic Inc.
🇺🇸Miami, Florida, United States
AppleMed Research Group LLC
🇺🇸Miami, Florida, United States
LCC Medical Research Institute Inc.
🇺🇸Miami, Florida, United States
Advanced Medical Research Institute
🇺🇸Miami, Florida, United States
Vilnius city Clinical hospital
🇱🇹Vilnius, Lithuania
Daugavpils Regional Hospital
🇱🇻Daugavpils, Latvia
NZOZ Centrum Urologiczne sp. z o.o.
🇵🇱Mysłowice, Woj. Slaskie, Poland
Montana Medical Research
🇺🇸Missoula, Montana, United States
NZOZ NOVITA Specjalistyczne Gabinety Lekarskie
🇵🇱Lublin, Woj. Lubelskie, Poland
Pauls Stradins Clinical University Hospital
🇱🇻Riga, Latvia
Vilnius
🇱🇹Vilnius, Lithuania
Montana Health Research Institute Inc.
🇺🇸Billings, Montana, United States
Szarka Ödön Egyesitett Egeszsegügyi es Szocialis Intezmeny
🇭🇺Csongrád, Hungary
ETG Lodz
🇵🇱Łódź, Woj. Lodzkie, Poland
Silverado Research Inc.
🇨🇦Victoria, British Columbia, Canada
Nzoz Heureka
🇵🇱Piaseczno, Woj. Mazowieckie, Poland
Clinical Research Consortium
🇺🇸Las Vegas, Nevada, United States
WR MCCCR
🇺🇸San Diego, California, United States
Excel Clinical Research
🇺🇸Las Vegas, Nevada, United States
Sentral Clinical Research Services
🇺🇸Cincinnati, Ohio, United States
Lynn Health Science Institute
🇺🇸Oklahoma City, Oklahoma, United States
Wasatch Clinical Research LLC
🇺🇸Salt Lake City, Utah, United States
Clinical Research Associates Inc.
🇺🇸Nashville, Tennessee, United States
Clinical Trials of Texas Inc.
🇺🇸San Antonio, Texas, United States
Bandera Family Health Care
🇺🇸San Antonio, Texas, United States
Fundamental Research LLC
🇺🇸Gulf Shores, Alabama, United States
Longwood Research
🇺🇸Huntsville, Alabama, United States
Coastal Clinical Research Inc.
🇺🇸Mobile, Alabama, United States
PAB Clinical Research
🇺🇸Brandon, Florida, United States
Riverside Clinical Research
🇺🇸Edgewater, Florida, United States
Pinellas Urology
🇺🇸Saint Petersburg, Florida, United States
Centex Studies Inc.
🇺🇸Houston, Texas, United States
CentraCare Clinic Adult & Pediatric Urology
🇺🇸Sartell, Minnesota, United States
United Medical Associates
🇺🇸Binghamton, New York, United States
Remidica LLC
🇺🇸Rochester, Michigan, United States
Barrett Clinic P.C.
🇺🇸La Vista, Nebraska, United States
Pioneer Clinical Research, LLC
🇺🇸Bellevue, Nebraska, United States
Sheldon Freedman MD Ltd
🇺🇸Las Vegas, Nevada, United States
Urologic Research and Consulting LLC
🇺🇸Englewood, New Jersey, United States
Lawrence OB-GYN Clinical Research LLC
🇺🇸Lawrenceville, New Jersey, United States
Smart Medical Research Inc.
🇺🇸Jackson Heights, New York, United States
AccuMed Research Associates
🇺🇸Garden City, New York, United States
ProHealth Care AssociatesLLP
🇺🇸Port Jefferson, New York, United States
Rochester Clinical Research Inc.
🇺🇸Rochester, New York, United States
PharmQuest
🇺🇸Greensboro, North Carolina, United States
Upstate Clinical Research Associates LLC
🇺🇸Williamsville, New York, United States
Raleigh Medical Group PMG Research of Raleigh
🇺🇸Raleigh, North Carolina, United States
PMG Research of Cary
🇺🇸Cary, North Carolina, United States
PMG Research of Salisbury
🇺🇸Salisbury, North Carolina, United States
Greater Providence Clinical Research, LLC
🇺🇸East Providence, Rhode Island, United States
Family Practice Center of Wadsworth Inc. - New Venture Medical Research
🇺🇸Wadsworth, Ohio, United States
Preferred Primary Care Physicians Inc.
🇺🇸Uniontown, Pennsylvania, United States
Hillcrest Clinical Research LLC
🇺🇸Simpsonville, South Carolina, United States
HWC Womens Research Center
🇺🇸Englewood, Ohio, United States
Clinical Research Solutions
🇺🇸Middleburg Heights, Ohio, United States
The Clinical Trial Center LLC
🇺🇸Jenkintown, Pennsylvania, United States
Green and Seidner Family Practice Associates P.C.
🇺🇸Lansdale, Pennsylvania, United States
Providence Health Partners
🇺🇸Dayton, Ohio, United States
Leonard Maliver MD Antria, Inc.
🇺🇸Indiana, Pennsylvania, United States
Omega Medical Research
🇺🇸Warwick, Rhode Island, United States
PMG Research of Charleston LLC
🇺🇸Mount Pleasant, South Carolina, United States
PEAK Research LLC
🇺🇸Upper Saint Clair, Pennsylvania, United States
Family Medicine of SayeBrook LLC
🇺🇸Myrtle Beach, South Carolina, United States
Palmetto Institute of Clinical Research Inc.
🇺🇸Pelzer, South Carolina, United States
WR - ClinSearch LLC
🇺🇸Chattanooga, Tennessee, United States
Volunteer Research Group - NOCCR
🇺🇸Knoxville, Tennessee, United States
The Jackson Clinic
🇺🇸Jackson, Tennessee, United States
Szent Anna Private Surgery
🇭🇺Debrecen, Hungary
DiscoveResearch Inc.
🇺🇸Bryan, Texas, United States
Discovery MM Services Inc.
🇺🇸Missouri City, Texas, United States
Mediroyal Prevention Center
🇭🇺Kecskemét, Hungary
Public Institution Republican Klaipda Hospital
🇱🇹Klaipėda, Lithuania
PrimeHealth Clinical Research
🇨🇦Toronto, Ontario, Canada
Millennium Clinical Trials
🇺🇸Arlington, Virginia, United States
Central Alberta Research Clinic
🇨🇦Red Deer, Alberta, Canada
Uro-clin Ltd
🇭🇺Pécs, Hungary
Central Alabama Research
🇺🇸Birmingham, Alabama, United States
Achieve Clinical Research
🇺🇸Birmingham, Alabama, United States
Horizons Clinical Research Center
🇺🇸Denver, Colorado, United States
Adult and Pediatric Urology P.C.
🇺🇸Omaha, Nebraska, United States
Adams Patterson Gynecology and Obstetrics
🇺🇸Memphis, Tennessee, United States
Drug Trials America
🇺🇸Hartsdale, New York, United States
Coastal Carolina Research Center
🇺🇸Mount Pleasant, South Carolina, United States
Ohio Clinical Research LLC
🇺🇸Willoughby Hills, Ohio, United States
Clinical Research Atlanta
🇺🇸Stockbridge, Georgia, United States
Indago Research Health Center
🇺🇸Hialeah, Florida, United States
Long Beach Clinical Trials LLC
🇺🇸Long Beach, California, United States
Revival Research
🇺🇸Doral, Florida, United States
Clinical Research Center of Florida
🇺🇸Pompano Beach, Florida, United States
Bioclinica Research
🇺🇸The Villages, Florida, United States
Saginaw Valley Medical Research
🇺🇸Saginaw, Michigan, United States
PMG Research of Wilmington, LLC
🇺🇸Wilmington, North Carolina, United States
Frontier Clinical Research, LLC
🇺🇸Smithfield, Pennsylvania, United States
Eclipse Clinical Research
🇺🇸Tucson, Arizona, United States
Dream Team Clinical Research LLC
🇺🇸Anaheim, California, United States
Noble Clinical Research
🇺🇸Tucson, Arizona, United States
Research Center of Fresno Inc.
🇺🇸Fresno, California, United States
Hope Clinical Research
🇺🇸Canoga Park, California, United States
Core Healthcare Group
🇺🇸Cerritos, California, United States
Marvel Clinical Research
🇺🇸Huntington Beach, California, United States
American Clinical Trials
🇺🇸Hawaiian Gardens, California, United States
Grossmont Center for Clinical Research
🇺🇸La Mesa, California, United States
Long Beach Clinical Trial Services Inc.
🇺🇸Long Beach, California, United States
Downtown L.A. Research Center Inc.
🇺🇸Los Angeles, California, United States
Urology Group of Southern California
🇺🇸Los Angeles, California, United States
Tri Valley Urology Medical Group
🇺🇸Murrieta, California, United States
San Bernadino Urological Associates
🇺🇸San Bernardino, California, United States
Artemis Institute for Clinical Research
🇺🇸San Marcos, California, United States
Empire Clinical Research
🇺🇸Upland, California, United States
Coastal Connecticut Research LLC
🇺🇸New London, Connecticut, United States
Bayview Research Group LLC
🇺🇸Valley Village, California, United States
Lynn Institute of Denver
🇺🇸Denver, Colorado, United States
Clinical Research Consulting LLC
🇺🇸Milford, Connecticut, United States
Chase Medical Research, LLC
🇺🇸Waterbury, Connecticut, United States
Innovative Medical Research of South Florida Inc.
🇺🇸Aventura, Florida, United States
Innovative Research of West FL Inc.
🇺🇸Clearwater, Florida, United States
Universal Medical and Research Center LLC
🇺🇸Coral Gables, Florida, United States
Top Medical Research Inc.
🇺🇸Cutler Bay, Florida, United States
Jesscan Medical Research
🇺🇸Delray Beach, Florida, United States
Health Awareness, Inc.
🇺🇸Jupiter, Florida, United States
A.G.A Clinical Trials
🇺🇸Hialeah, Florida, United States
Nuren Medical Research Center
🇺🇸Miami, Florida, United States
Miami Clinical Research
🇺🇸Miami, Florida, United States
Suncoast Clinical Research Inc.
🇺🇸New Port Richey, Florida, United States
Bayside Clinical Research
🇺🇸New Port Richey, Florida, United States
Meridien Research
🇺🇸Spring Hill, Florida, United States
Asclepes Research Centers
🇺🇸Weeki Wachee, Florida, United States
Clinical Research of Central Florida
🇺🇸Winter Haven, Florida, United States
In-Quest Medical Research, LLC
🇺🇸Peachtree Corners, Georgia, United States
Advanced Clinical Research
🇺🇸West Jordan, Utah, United States
Elite Clinical Trials
🇺🇸Blackfoot, Idaho, United States
Meridian Clinical Research LLC
🇺🇸Norfolk, Nebraska, United States
Evanston Premier Healthcare Research
🇺🇸Evanston, Illinois, United States
Investigators Research Group LLC
🇺🇸Brownsburg, Indiana, United States
Clinical Investigation Specialists Inc.
🇺🇸Gurnee, Illinois, United States
MediSphere Medical Research Center
🇺🇸Evansville, Indiana, United States
Heartland Research Associates LLC
🇺🇸Wichita, Kansas, United States
Regional Urology LLC
🇺🇸Shreveport, Louisiana, United States
Chesapeake Urology Research Associates
🇺🇸Hanover, Maryland, United States
BTC of New Bedford
🇺🇸New Bedford, Massachusetts, United States
Regeneris Medical
🇺🇸North Attleboro, Massachusetts, United States
Infinity Medical Research Inc.
🇺🇸North Dartmouth, Massachusetts, United States
Bay State Clinical Trials Inc.
🇺🇸Watertown, Massachusetts, United States
Beacon Clinical Research
🇺🇸Quincy, Massachusetts, United States
Poplar Bluff Urology
🇺🇸Poplar Bluff, Missouri, United States
Women's Clinic of Lincoln PC
🇺🇸Lincoln, Nebraska, United States
Premier Urology Group LLC
🇺🇸Edison, New Jersey, United States
Quality Clinical Research Inc.
🇺🇸Omaha, Nebraska, United States
Hassman Research Institute
🇺🇸Berlin, New Jersey, United States
Regional Clinical Research Inc.
🇺🇸Endwell, New York, United States
PMG Research of Charlotte LLC
🇺🇸Charlotte, North Carolina, United States
Peters Medical Research
🇺🇸High Point, North Carolina, United States
Associated Urologists of North Carolina
🇺🇸Raleigh, North Carolina, United States
PMG Research
🇺🇸Wilmington, North Carolina, United States
Rapid Medical Research
🇺🇸Cleveland, Ohio, United States
Clinical Research of Philadelphia LLC
🇺🇸Philadelphia, Pennsylvania, United States
DeGarmo Institute of Medical Research
🇺🇸Greer, South Carolina, United States
Piedmont Research Partners
🇺🇸Fort Mill, South Carolina, United States
Palmetto Clinical Research
🇺🇸Summerville, South Carolina, United States
MultiSpecialty Clinical Research, Inc.
🇺🇸Johnson City, Tennessee, United States
Village Health Partners ACRC Trials
🇺🇸Plano, Texas, United States
Protenium Clinical Research
🇺🇸Hurst, Texas, United States
Clinova Clinical Trials
🇺🇸Spring, Texas, United States
Progressive Clinical Research
🇺🇸Bountiful, Utah, United States
Health Research of Hampton Roads Inc.
🇺🇸Newport News, Virginia, United States
Seattle Urology Research
🇺🇸Burien, Washington, United States
North Spokane Womens Health
🇺🇸Spokane, Washington, United States
Obudai Egeszsegugyi Centrum Kft.
🇭🇺Budapest, Hungary
Manna Research (Quebec)
🇨🇦Levis, Quebec, Canada
Recherche GCP Research
🇨🇦Montreal, Quebec, Canada
Diex Research Sherbrooke Inc.
🇨🇦Sherbrooke, Quebec, Canada
Manna Research (Montreal)
🇨🇦Montréal, Quebec, Canada
Uro Ltd.
🇱🇻Riga, Latvia
Poradnia Urologiczna EuroMediCare Szpital Specjalistyczny z Przychodnia
🇵🇱Wrocław, Woj. Dolnoslaskie, Poland
Klimed Marek Klimkiewicz
🇵🇱Białystok, Woj. Podlaskie, Poland
Northern California Research
🇺🇸Sacramento, California, United States
Compass Research LLC
🇺🇸Orlando, Florida, United States
Clinical Research of West Florida
🇺🇸Tampa, Florida, United States
Carolina Medical Trials LLC
🇺🇸Winston-Salem, North Carolina, United States
PMG Research of Winston-Salem
🇺🇸Winston-Salem, North Carolina, United States
L-MARC Research Center
🇺🇸Louisville, Kentucky, United States
DelRicht Research
🇺🇸New Orleans, Louisiana, United States
Pharmacorp Clinical Trials Inc.
🇺🇸Charleston, South Carolina, United States
Clinical Trials of South Carolina
🇺🇸Charleston, South Carolina, United States
Central Kentucky Research Associates Inc.
🇺🇸Lexington, Kentucky, United States
Albuquerque Clinical Trials, Inc.
🇺🇸Albuquerque, New Mexico, United States
AccumetRx Clinical Research - Division of Urology Group of New Mexico
🇺🇸Albuquerque, New Mexico, United States
Avail Clinical Research
🇺🇸DeLand, Florida, United States
North Georgia Clinical Research
🇺🇸Woodstock, Georgia, United States
WR Global Medical Research
🇺🇸DeSoto, Texas, United States
PMG Research of Bristol LLC
🇺🇸Bristol, Tennessee, United States